The press releases are available in Swedish when no translation exists.
Chordate Medical's CEO Anders Weilandt will participate on BioStock Life Science Spring Summit on June 8th, at 11:20. He will present the latest developments in the company, such as the recently completed first phase of the marketing authorization process in the United States, the upcoming representative office in Saudi Arabia and the marketing efforts in the United Kingdom.
"Biostocks Life Science Summit events is an important platform for Nordic innovation companies such as Chordate. I look forward to talking about what we have done so far in 2022 and what we have planned for the rest of the year and beyond," says Anders Weilandt, Chordate CEO.
BioStock Life Science Spring Summit will be livestreamed at Biostocks Youtube channel:
Read more about the event: https://www.biostock.se/en/2022/04/biostock-life-science-spring-summit-june-8-9/
For more information, please contact:Anders Weilandt, CEOanders.firstname.lastname@example.orgCell: +46 733-874277
About ChordateChordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel, and Saudi Arabia. Chordate Medicals share is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com
Chordate's Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB, +46 40 200 250, email@example.com.
Press releases and reports via E-mail.
We are a Swedish medical technology company listed on Nasdaq First North Growth Market.
Chordate has spent more than 10 years developing the Kinetic Oscillation Stimulation, K.O.S, a technique for treating rhinitis and migraine. We have a patent on K.O.S in the EU and the United States, as well as many other countries.
We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.
Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company's share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.